Venous ThrombosisNCT03317145
Lower Limb Blood Flow Geko vs Foot Pump
A study testing Neuromuscular electrostimulation (NMES) device and Intermittent pneumatic compression (IPC) device in people with Venous Thrombosis and Arthroplasty, Replacement, Hip, run by Hampshire Hospitals NHS Foundation Trust.
Trial summary
The aim of this pilot study was to assess venous flow parameters in patients following total hip arthroplasty, comparing an intermittent pneumatic compression foot device with a portable neuromuscular electrostimulator device. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Venous Thrombosis, Arthroplasty, Replacement, Hip
- What is being tested?
- Neuromuscular electrostimulation (NMES) device and Intermittent pneumatic compression (IPC) device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- No sites listed yet
- Study dates
- 24 Jul 2013to 19 Feb 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients undergoing primary THA,
- in good general health and fitness,
- age 18 years or over
- able to provide written informed consent.
Who cannot join
- Are requiring hip revision surgery
- Previous or current diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE).
- History or signs of significant haematological disorders (especially in relation to clotting or coagulation) or thrombophlebitis.
- Peripheral arterial disease, clinically significant varicose veins or lower limb ulceration or ischemia.
- Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement).
- Recent trauma to lower limb.
Show all 15Show fewer
- Chronic Obesity (BMI Index >40kg/m2).
- Pregnancy.
- Significant history of following diseases i. Cardiovascular: Recent MI (< 6 months) ii. Percutaneous Coronary Intervention (PCI) with stent (< 3 months for Bare metal stent (BMS) and < 12 months for Drug Eluding Stent (DES) iii. Moderate to severe CCF, uncontrolled AF iv. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies v. Renal: Moderate to severely impaired renal function vi. Hepatic: Moderate to severely impaired hepatic function vii. Psychiatric disorders viii. Dermatological conditions affecting lower limbs
- On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or warfarin stopped recently and replaced by LMWH/ Heparin
- Long term steroid use with dermatological changes
- A pulse rate of less than 40 beats/minute
- A sitting systolic blood pressure >180 and <100 mmHg and/or a sitting diastolic pressure of >100 mmHg.
- Participation in any clinical study during the eight (8) weeks preceding the screening period
- THR done for hip fracture
About this study
Official title: Intermittent Pneumatic Compression (IPC) of the Foot Versus Geko™ Neuromuscular Electrostimulation (NMES): Comparison of Lower Limb Circulation Following Elective Total Hip Replacement (THR)
The aim of this pilot study was to assess venous flow parameters in patients following total hip arthroplasty, comparing an intermittent pneumatic compression foot device with a portable neuromuscular electrostimulator device. Assessments were performed in a single sitting before hospital discharge, between days 1 to 4 post operatively. The total duration of participation for each patient who completed the study was approximately 2.5 hours.
Read the detailed description
Ethical approval was obtained from the National Research Ethics Service (Edgbaston), reference 13/WM/0139. Upon admission to hospital for THA, eligible patients were invited to participate in the study. Inclusion criteria were: patients undergoing primary THA, in good general health and fitness, age 18 years or over and the ability to provide written informed consent. Patients were taken to the ultrasound suite within the first three days following surgery.
Baseline ultrasound Patients lay in bed, the back supported at approximately 45 degrees, legs lying horizontal with their knees extended. Duplex ultrasound was then performed on the superficial femoral vein (Acuson S2000, Siemens). Baseline bilateral venous assessments of peak velocity, mean velocity, volume flow and vessel diameter were taken in triplicate. All scans were performed by the same ultrasonographer for consistency. Gate size was adjusted to just within the vessel wall.
Randomisation Following baseline measurements, patients were fitted with either the NMES device or an IPC device, the order determined by randomisation using online software. A representative from the study sponsor provided sealed envelopes containing the arm to be randomised which was opened on the day of testing.
Patients were randomised into arm A (NMES first, IPC second) or arm B (IPC first, NMES second). Blinding was not possible because the obvious physical differences between the two devices. Following testing of the first device, a 30-minute rest period was then given. The second device was then tested. All devices were fitted by the first author. All patients underwent scanning by the same sonographer to ensure consistency in data recording.
NMES application The NMES device (Geko T-1, Firstkind Ltd., High Wycombe, United Kingdom) was applied to both legs as per the manufacturer's instructions. The skin over the fibula head was prepared with an exfoliation pad, followed by an alcohol wipe. The device was applied to the skin using an adhesive strip and positioned so that the built-in electrodes were positioned over the common peroneal nerve. An overlay strip was then used to improve skin contact. A charge balanced short single pulse with a current of 27mA was delivered at a frequency of once per second. The pulse width adjustment has seven selectable stimulation settings ranging from 70 - 560 μs and was increased until a visible foot twitch was produced. Following successful application of the device for ten minutes, venous blood flow measurements were repeated.
IPC application
An IPC device (Vadoplex, OPED UK, UK) was fitted to each foot as per the manufacturer's instructions and activated for ten minutes prior to recording venous flow. The IPC provides a pump inflation pressure of 120mmHg, inflating once every 20 seconds. Each inflation was maintained for approximately 1 second, before deflation occurred. The maximum recording duration of the ultrasound scanner was 14 seconds. In order to capture 20 seconds of data, two contiguous measurements of 14 and 6 seconds were made. The machine records flow within the vessel. Since flow varies within the vessel, the machine is able to use a complex algorithm to sample velocities and flow over time and hence calculate the mean. In order to calculate mean velocity and volume flow over a complete 20 second cycle, we used the following equation:
- Measure the blood flow during inflation (F1) and record the time duration of this flow (A).
- Measure the blood flow during the opposite, deflated, part of the cycle (F2) and record the total cycle duration (B).
The calculation below provides a summated value for flow.
Total flow = [(A/B) x F1)] + [(1-(A/B)) x F2]
Device acceptability Patients were asked to rate comfort of the devices using a verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.
Power analysis and statistical analysis Data from an unpublished study in healthy volunteers of the NMES device verses IPC comparing venous flow parameters, showed a significant benefit of NMES, with an effect size of 1.4 (Cohen's d). Sample size calculation based on this effect size gave a power in excess of 90% for a design of ten subjects per site.
We checked for significant association (p<0.05) of device, measurement order and leg on blood flow parameters of interest using generalized linear latent and mixed model with a random effects term to account for repeated measures on a given subject using Stata10 (Stata Corp, college station, TX). Blood flow parameters are reported as mean and 95% confidence intervals (CI). A Wilcoxon signed rank test was used to analyse the verbal rating scores for patient comfort.
- Conditions
- Venous Thrombosis, Arthroplasty, Replacement, Hip
- Being tested
- Neuromuscular electrostimulation (NMES) device, Intermittent pneumatic compression (IPC) device
- Keywords
- venous thromboembolism, deep vein thrombosis, pulmonary embolism, neuromuscular electrostimulation, foot compression, hip replacement
- Medical subject headings
- Venous Thrombosis, Venous Thromboembolism, Pulmonary Embolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuromuscular electrostimulation (NMES) deviceDevice
Also called Geko T-1
A mobile peroneal nerve stimulator
Intermittent pneumatic compression (IPC) deviceDevice
Also called Vadoplex
A foot pump or foot compression device
| Study group | Role | What they receive |
|---|---|---|
| Arm A (NMES followed by IPC) | Active comparator | Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated. Receives: Device: Neuromuscular electrostimulation (NMES) device; Device: Intermittent pneumatic compression (IPC) device |
| Arm B (IPC followed by NMES) | Active comparator | Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated Receives: Device: Neuromuscular electrostimulation (NMES) device; Device: Intermittent pneumatic compression (IPC) device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Venous flow at baseline
Measured within the superficial femoral vein using ultrasound
Measured: "t0" - 30 minutes to include the ultrasound assessment, performed between days 1 and 4 post operatively
Venous flow after application of device 1
Measured within the superficial femoral vein using ultrasound
Measured: "t1" - 90 minutes to include the ultrasound assessment
Venous flow after application of device 2
Measured within the superficial femoral vein using ultrasound
Measured: "t2" - 150 minutes to include the ultrasound assessment
Secondary outcomes (2)
Patient satisfaction with device 1
verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.
Measured: Immediately after completion of the ultrasound assessment for device 1, at "t1" - 90 minutes
Patient satisfaction with device 2
verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.
Measured: Immediately after completion of the ultrasound assessment for device 2, at "t2" - 150 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2017
- Study start24 Jul 2013
- Primary completion19 Feb 2014
- Study completion19 Feb 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Venous ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- Patients who have had a total hip replacement will be randomised to wear either a foot compression (IPC) device or a neuromuscular electrostimulation (NMES) device (gekoTM) first. Blood flow will be measured using both devices on the same patient in sequence. The blood flow measurements will be done by ultrasound. Each ultrasound assessment will take approximately 30 minutes in total. Baseline blood flow measurements will be taken initially. The first device will then be fitted and allowed to operate for 10 minutes before ultrasound measurements are taken. After a rest period of 30 minutes, the second device is then fitted and allowed to operate for 10 minutes, following which blood flow measurements are repeated. Patients will then be asked to complete a questionnaire to assess the comfort of each device.
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hampshire Hospitals NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Firstkind Ltd
- Responsible party
- Sponsor
- Investigators
- Geoff Stranks, FRCS, Principal investigator, North Hampshire Hospital, Basingstoke
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03317145
- Sponsor's protocol ID
- FSK-FP-001
- Status last verified
- Oct 2017
- First submitted
- 12 Oct 2017
- Last updated
- 21 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We would be happy to share individual participant data if requested by other researchers although have no formal plans to publish this at present. All data shared would be anonymised.
Publications
Warwick DJ, Shaikh A, Gadola S, Stokes M, Worsley P, Bain D, Tucker AT, Gadola SD. Neuromuscular electrostimulation viathe common peroneal nerve promotes lower limb blood flow in a below-kneecast: A potential for thromboprophylaxis. Bone Joint Res. 2013 Sep 2;2(9):179-85. doi: 10.1302/2046-3758.29.2000176. Print 2013.
PubMed 23999610Williams KJ, Moore HM, Davies AH. Haemodynamic changes with the use of neuromuscular electrical stimulation compared to intermittent pneumatic compression. Phlebology. 2015 Jun;30(5):365-72. doi: 10.1177/0268355514531255. Epub 2014 Apr 10.
PubMed 24722790
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intermittent Pneumatic Compression (IPC) of the Foot Versus Geko™ Neuromuscular Electrostimulation (NMES): Comparison of Lower Limb Circulation Following Elective Total Hip Replacement (THR)
- ClinicalTrials.gov ID
- NCT03317145
- Acronym / sponsor ID
- FSK-FP-001
- Conditions
- Venous Thrombosis, Arthroplasty, Replacement, Hip
- Keywords
- venous thromboembolism, deep vein thrombosis, pulmonary embolism, neuromuscular electrostimulation, foot compression, hip replacement
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Hampshire Hospitals NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Firstkind Ltd
- Study start
- 24 Jul 2013 (actual)
- Primary completion
- 19 Feb 2014 (actual)
- Study completion
- 19 Feb 2014 (actual)
- First posted
- 23 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this pilot study was to assess venous flow parameters in patients following total hip arthroplasty, comparing an intermittent pneumatic compression foot device with a portable neuromuscular electrostimulator device. Assessments were performed in a single sitting before hospital discharge, between days 1 to 4 post operatively. The total duration of participation for each patient who completed the study was approximately 2.5 hours.
Detailed description
Ethical approval was obtained from the National Research Ethics Service (Edgbaston), reference 13/WM/0139. Upon admission to hospital for THA, eligible patients were invited to participate in the study. Inclusion criteria were: patients undergoing primary THA, in good general health and fitness, age 18 years or over and the ability to provide written informed consent. Patients were taken to the ultrasound suite within the first three days following surgery.
Baseline ultrasound Patients lay in bed, the back supported at approximately 45 degrees, legs lying horizontal with their knees extended. Duplex ultrasound was then performed on the superficial femoral vein (Acuson S2000, Siemens). Baseline bilateral venous assessments of peak velocity, mean velocity, volume flow and vessel diameter were taken in triplicate. All scans were performed by the same ultrasonographer for consistency. Gate size was adjusted to just within the vessel wall.
Randomisation Following baseline measurements, patients were fitted with either the NMES device or an IPC device, the order determined by randomisation using online software. A representative from the study sponsor provided sealed envelopes containing the arm to be randomised which was opened on the day of testing.
Patients were randomised into arm A (NMES first, IPC second) or arm B (IPC first, NMES second). Blinding was not possible because the obvious physical differences between the two devices. Following testing of the first device, a 30-minute rest period was then given. The second device was then tested. All devices were fitted by the first author. All patients underwent scanning by the same sonographer to ensure consistency in data recording.
NMES application The NMES device (Geko T-1, Firstkind Ltd., High Wycombe, United Kingdom) was applied to both legs as per the manufacturer's instructions. The skin over the fibula head was prepared with an exfoliation pad, followed by an alcohol wipe. The device was applied to the skin using an adhesive strip and positioned so that the built-in electrodes were positioned over the common peroneal nerve. An overlay strip was then used to improve skin contact. A charge balanced short single pulse with a current of 27mA was delivered at a frequency of once per second. The pulse width adjustment has seven selectable stimulation settings ranging from 70 - 560 μs and was increased until a visible foot twitch was produced. Following successful application of the device for ten minutes, venous blood flow measurements were repeated.
IPC application
An IPC device (Vadoplex, OPED UK, UK) was fitted to each foot as per the manufacturer's instructions and activated for ten minutes prior to recording venous flow. The IPC provides a pump inflation pressure of 120mmHg, inflating once every 20 seconds. Each inflation was maintained for approximately 1 second, before deflation occurred. The maximum recording duration of the ultrasound scanner was 14 seconds. In order to capture 20 seconds of data, two contiguous measurements of 14 and 6 seconds were made. The machine records flow within the vessel. Since flow varies within the vessel, the machine is able to use a complex algorithm to sample velocities and flow over time and hence calculate the mean. In order to calculate mean velocity and volume flow over a complete 20 second cycle, we used the following equation:
- Measure the blood flow during inflation (F1) and record the time duration of this flow (A).
- Measure the blood flow during the opposite, deflated, part of the cycle (F2) and record the total cycle duration (B).
The calculation below provides a summated value for flow.
Total flow = [(A/B) x F1)] + [(1-(A/B)) x F2]
Device acceptability Patients were asked to rate comfort of the devices using a verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.
Power analysis and statistical analysis Data from an unpublished study in healthy volunteers of the NMES device verses IPC comparing venous flow parameters, showed a significant benefit of NMES, with an effect size of 1.4 (Cohen's d). Sample size calculation based on this effect size gave a power in excess of 90% for a design of ten subjects per site.
We checked for significant association (p<0.05) of device, measurement order and leg on blood flow parameters of interest using generalized linear latent and mixed model with a random effects term to account for repeated measures on a given subject using Stata10 (Stata Corp, college station, TX). Blood flow parameters are reported as mean and 95% confidence intervals (CI). A Wilcoxon signed rank test was used to analyse the verbal rating scores for patient comfort.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Patients who have had a total hip replacement will be randomised to wear either a foot compression (IPC) device or a neuromuscular electrostimulation (NMES) device (gekoTM) first. Blood flow will be measured using both devices on the same patient in sequence. The blood flow measurements will be done by ultrasound. Each ultrasound assessment will take approximately 30 minutes in total. Baseline blood flow measurements will be taken initially. The first device will then be fitted and allowed to operate for 10 minutes before ultrasound measurements are taken. After a rest period of 30 minutes, the second device is then fitted and allowed to operate for 10 minutes, following which blood flow measurements are repeated. Patients will then be asked to complete a questionnaire to assess the comfort of each device.
| Arm | Type | Receives |
|---|---|---|
| Arm A (NMES followed by IPC) | Active comparator | Device: Neuromuscular electrostimulation (NMES) device, Device: Intermittent pneumatic compression (IPC) deviceArm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated. |
| Arm B (IPC followed by NMES) | Active comparator | Device: Neuromuscular electrostimulation (NMES) device, Device: Intermittent pneumatic compression (IPC) deviceArm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- patients undergoing primary THA,
- in good general health and fitness,
- age 18 years or over
- able to provide written informed consent.
Key exclusion criteria (15 listed)
- Are requiring hip revision surgery
- Previous or current diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE).
- History or signs of significant haematological disorders (especially in relation to clotting or coagulation) or thrombophlebitis.
- Peripheral arterial disease, clinically significant varicose veins or lower limb ulceration or ischemia.
- Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuromuscular electrostimulation (NMES) deviceAlso: Geko T-1A mobile peroneal nerve stimulator | Device | Arm A (NMES followed by IPC), Arm B (IPC followed by NMES) |
| Intermittent pneumatic compression (IPC) deviceAlso: VadoplexA foot pump or foot compression device | Device | Arm A (NMES followed by IPC), Arm B (IPC followed by NMES) |
Primary outcome
Venous flow at baseline
Time frame: "t0" - 30 minutes to include the ultrasound assessment, performed between days 1 and 4 post operatively
Measured within the superficial femoral vein using ultrasound
Venous flow after application of device 1
Time frame: "t1" - 90 minutes to include the ultrasound assessment
Measured within the superficial femoral vein using ultrasound
Venous flow after application of device 2
Time frame: "t2" - 150 minutes to include the ultrasound assessment
Measured within the superficial femoral vein using ultrasound
2 secondary outcomes
Patient satisfaction with device 1
Time frame: Immediately after completion of the ultrasound assessment for device 1, at "t1" - 90 minutes
Patient satisfaction with device 2
Time frame: Immediately after completion of the ultrasound assessment for device 2, at "t2" - 150 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2021.
- Background: PubMed 23999610Warwick DJ, Shaikh A, Gadola S, Stokes M, Worsley P, Bain D, Tucker AT, Gadola SD. Neuromuscular electrostimulation viathe common peroneal nerve promotes lower limb blood flow in a below-kneecast: A potential for thromboprophylaxis. Bone Joint Res. 2013 Sep 2;2(9):179-85. doi: 10.1302/2046-3758.29.2000176. Print 2013.
- Background: PubMed 24722790Williams KJ, Moore HM, Davies AH. Haemodynamic changes with the use of neuromuscular electrical stimulation compared to intermittent pneumatic compression. Phlebology. 2015 Jun;30(5):365-72. doi: 10.1177/0268355514531255. Epub 2014 Apr 10.
- Individual participant dataSharing planned: No. We would be happy to share individual participant data if requested by other researchers although have no formal plans to publish this at present. All data shared would be anonymised.
Related trials for Venous Thrombosis
RecruitingPhase 4
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Multiple Myeloma, Venous Thromboembolism (VTE)
Not yet recruitingObservational study
Construction and Multicenter External Validation of an Early Warning Model for Asymptomatic PICC-related Upper Extremity Venous Thrombosis in Cancer Patients Based on LASSO-XGBoost
PICC-associated Thrombosis
Not yet recruitingObservational study
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Age- Related Macular Degeneration, Diabetic Retinopathy
RecruitingObservational study
Danang Cerebral Venous Thrombosis Registry
Cerebral Venous Sinus Thrombosis, Stroke
Recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study
Venous Thromboses, Venous Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Geoff Stranks, FRCS principal investigator
North Hampshire Hospital, Basingstoke
Questions about this trial
What is this clinical trial studying?
A study testing Neuromuscular electrostimulation (NMES) device and Intermittent pneumatic compression (IPC) device in people with Venous Thrombosis and Arthroplasty, Replacement, Hip, run by Hampshire Hospitals NHS Foundation Trust.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Venous flow at baseline (time frame: "t0" - 30 minutes to include the ultrasound assessment, performed between days 1 and 4 post operatively). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03317145, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2021.